Fig. 6

Delivery of LV-NR-R80Q-apoB ameliorates the neurodegenerative pathology in MBP-α-syn tg mice. Serial longitudinal vibratome sections were analyzed by bright field microscopy. Top row represents a low power overview (40X) of the section and panels in the bottom row show a higher magnification view (400X) of the striatum. a Immunohistochemical analysis with an antibody against the neuronal marker NeuN in brain sections of non-tg mice or MBP-α-syn tg mice injected with LV-Control, or LV-NR-R80Q-apoB vector. b, c Stereological analysis using the dissector method to estimate the total numbers of NeuN-positive cells in the frontal cortex and striatum. d Immunohistochemical analysis with an antibody against the astrocyte marker GFAP in brain sections of non-tg mice or MBP-α-syn tg mice injected with LV-Control, or LV-NR-R80Q-apoB vector. e, f Semiquantitative analysis of levels of GFAP immunostaining by optical density in the corpus callosum and striatum. g Immunohistochemical analysis with an antibody against the microglial marker Iba-1 in brain sections of non-tg mice or MBP-α-syn tg mice injected with LV-Control, or LV-NR-R80Q-apoB vector. h, i Stereological analysis using the dissector method to estimate the total numbers of Iba-1 positive cells in the frontal cortex and striatum. n = 10 mice per group 9–10 m/o at the end of the treatment. Scale bar = in the lower magnification panels 250 μm and in the higher magnification panels 50 μm. * indicates statistical significance (p < 0.05, one way ANOVA, post hoc Dunnett’s) compared to LV-control, non-tg mice. # indicates statistical significance (p < 0.05, one way ANOVA, post hoc Tukey-Kramer) compared to LV-Control treated MBP-α-syn tg mice